+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Thromboembolism Drug"

Venous Thromboembolism - Pipeline Insight, 2024 - Product Thumbnail Image

Venous Thromboembolism - Pipeline Insight, 2024

  • Clinical Trials
  • April 2024
  • 50 Pages
  • Global
From
From
Venous Thromboembolism Global Market Report 2024 - Product Thumbnail Image

Venous Thromboembolism Global Market Report 2024

  • Report
  • January 2024
  • 175 Pages
  • Global
From
From
From
Venous Thromboembolism - Epidemiology Forecast to 2032 - Product Thumbnail Image

Venous Thromboembolism - Epidemiology Forecast to 2032

  • Report
  • January 2022
  • 60 Pages
  • Global
From
Market Spotlight: Venous Thromboembolism (VTE) - Product Thumbnail Image

Market Spotlight: Venous Thromboembolism (VTE)

  • Report
  • February 2021
  • 36 Pages
  • Global
Venous Thromboembolism Market and Forecast Analysis to 2026 - Product Thumbnail Image

Venous Thromboembolism Market and Forecast Analysis to 2026

  • Drug Pipelines
  • February 2018
  • 373 Pages
  • Global
From
Venous Thromboembolism Global Clinical Trials Review, H1, 2020 - Product Thumbnail Image

Venous Thromboembolism Global Clinical Trials Review, H1, 2020

  • Clinical Trials
  • February 2020
  • 553 Pages
  • Global
From
Market Spotlight: Atrial Fibrillation - Product Thumbnail Image

Market Spotlight: Atrial Fibrillation

  • Report
  • April 2021
  • 48 Pages
  • Global
Arterial Thrombosis - Pipeline Review, H2 2020 - Product Thumbnail Image

Arterial Thrombosis - Pipeline Review, H2 2020

  • Drug Pipelines
  • September 2020
  • 40 Pages
  • Global
From
Loading Indicator

The Thromboembolism Drug market is a subset of the Cardiovascular Drugs market, which focuses on the prevention and treatment of thromboembolic diseases. These drugs are used to reduce the risk of blood clots forming in the arteries and veins, which can lead to serious health complications such as stroke, heart attack, and pulmonary embolism. Thromboembolism drugs are typically anticoagulants, which work by preventing the formation of clots, or thrombolytics, which work by breaking down existing clots. The Thromboembolism Drug market is highly competitive, with a range of products available from both generic and branded manufacturers. Commonly prescribed drugs include warfarin, heparin, and low molecular weight heparins. Newer drugs such as direct oral anticoagulants (DOACs) are also becoming increasingly popular. Some of the major companies in the Thromboembolism Drug market include Pfizer, Sanofi, Bayer, Bristol-Myers Squibb, and Boehringer Ingelheim. Show Less Read more